Cypher versus taxus: Are there differences?

Journal of Interventional Cardiology

Volumn 18, Issue 6, 2005, Pages 441-446

  Silber, Sigmund ^a,b  

^a Cardiology Practice and Hospital   (Germany)

^b Cardiology Practice and Hospital ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; POLYMER; RAPAMYCIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING STENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWITZERLAND; TREATMENT OUTCOME; UNITED STATES;

BLOOD VESSEL PROSTHESIS IMPLANTATION; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 28444474176     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2005.00084.x     Document Type: Conference Paper

References (23)

1. Park SJ, Shim WH, Ho DS, et al. A Paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-1545.
2. Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a Paclitaxel-eluting, polymer-free coronary stent: The European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 2004;109:487-193.
3. Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based Paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: Angiographic follow-up of the DELIVER clinical trial. Circulation 2004;109:1948-1954.
4. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release Paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-12.
5. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based Paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
6. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, Paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
7. Stone GW. Outcomes of the polymer-based Paclitaxel-eluting TAXUS stent in complex lesions (TAXUS V). Presented at ACC late breaking trials, 54th Annual Scientific Session, Orlando, USA, 2005.
8. Dawkins K. TAXUS VI: Angiographic results and QCA analysis. EuroPCR Paris, late breaking trials, May 2004.
9. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a Sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
10. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
11. Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
12. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the Sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-1115.
13. Kelbaek H. Randomized multicenter comparison of Sirolimus vs. bare metal stent implantation in complex coronary artery disease (SCANDSTENT). Presented at ACC late breaking trials, 54th Annual Scientific Session, Orlando, USA, 2005.
14. Grube E, Sonoda S, Ikeno F, et al. Six- and twelve-month results from first human experience using Everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-2171.
15. Grube E. Everolimus-eluting stent for the prevention of restenosis: Results of the FUTURE-II trial. Presented at TCT, late breaking trials, Washington, DC, USA, 2003.
16. Serruys P. SPIRIT FIRST: Baseline and 6-month follow-up results. Presented at TCT, Great Clinical Trials from Europe, Washington, DC, USA, 2004.
17. Abizaid A. First in man experience of the Biolimus A9 drug-eluting stent (BioMatrix Stent) in treatment of de-novo coronary lesions: 6 months results from the STEALTH-1 trial. Presented at AHA Annual Scientific Sessions, New Orleans, USA, 2004.
18. Wijns W. A randomized trial to evaluate the safety and efficacy of the Medtronic AVE ABT-578 eluting driver coronary stent in de-novo native coronary artery lesions (ENDEAVOR-II). Presented at ACC late breaking trials, 54th Annual Scientific Session, Orlando, USA, 2005.
19. Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized comparison between Paclitaxel and Sirolimus stents in the real world of interventional cardiology: The TAXi trial. J Am Coll Cardiol 2005;45:308-311.
20. Morice MC. A prospective, randomized, multi-center comparison study of the CYPHER Sirolimus-eluting and TAXUS Paclitaxel-eluting stent system (REALITY). Presented at ACC late breaking trials, 54th Annual Scientific Session, Orlando, USA, 2005.
21. Windecker S. A randomized comparison of a Sirolimus with a Paclitaxel eluting stent for coronary revascularization: The SIR-TAX trial. Presented at ACC late breaking trials, 54th Annual Scientific Session, Orlando, USA, 2005.
22. Kastrati A. Paclitaxel-eluting stent versus Sirolimus-eluting stent for the prevention of restenosis in diabetic patients with coronary artery disease: ISAR DIABETES. Presented at ACC late breaking trials, 54th Annual Scientific Session, Orlando, USA, 2005.
23. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-847.